Method for the in vitro diagnosis or prognosis of testicular cancer
AssigneeBiomerieux
InventorsJuliette GIMENEZ, Cecile MONTGIRAUD, Francois MALLET
Life of this patent
Estimating the term…
Abstract
A method for in vitro diagnosis of testicular cancer includes (i) obtaining a biological sample from a patient suspected of having testicular cancer, (ii) performing an assay to determine the methylation status of CpG dinucleotides in a genomic DNA target sequence, the DNA target sequence being the 5′ LTR U3 promoter sequence of the ERVWE1 locus, optionally further including an activator sequence directly upstream of the 5′ LTR U3 promoter sequence, and (iii) diagnosing the patient with testicular cancer when the DNA target sequence is hypomethylated as compared to a methylation status indicative of the absence of testicular cancer.
Claims14
A method for in vitro diagnosis of testicular cancer, comprising:
- obtaining a biological sample from a patient suspected of having testicular cancer;
- performing an assay to determine the methylation status of CpG dinucleotides in a genomic DNA target sequence, the DNA target sequence being at least one sequence selected from the group consisting of sequences having at least 99% sequence identity with the full-length sequence of SEQ ID NO:
- 6 or 7 and the sequences fully complementary thereto;
- and
- diagnosing the patient with testicular cancer when the DNA target sequence is hypomethylated as compared to a methylation status indicative of the absence of testicular cancer,
- wherein the assay comprises:
- extracting genomic DNA from the biological sample;
- treating the extracted genomic DNA to convert cytosine bases of CpG dinucleotides that are nonmethylated at position 5 into uracil bases;
- amplifying the treated genomic DNA target sequence;
- and
- determining the methylation status of the CpG dinucleotides in the genomic DNA target sequence from the amplified genomic DNA target sequence.
A method for in vitro diagnosis of testicular cancer, comprising:
- obtaining a biological sample from a patient suspected of having testicular cancer;
- performing an assay to determine the methylation status of CpG dinucleotides in a genomic DNA target sequence, the DNA target sequence being the 5′ LTR U3 promoter sequence of the ERVWE1 locus, optionally further including an activator sequence directly upstream of the 5′ LTR U3 promoter sequence;
- and
- diagnosing the patient with testicular cancer when the DNA target sequence is hypomethylated as compared to a methylation status indicative of the absence of testicular cancer,
- wherein the assay comprises:
- extracting genomic DNA from the biological sample;
- treating the extracted genomic DNA to convert cytosine bases of CpG dinucleotides that are nonmethylated at position 5 into uracil bases;
- amplifying the treated genomic DNA target sequence;
- and
- determining the methylation status of the CpG dinucleotides in the genomic DNA target sequence from the amplified genomic DNA target sequence.
Dependencies are inferred from the claim text.